Rifasutenizol
- Generic Name
- Rifasutenizol
TenNor's Rifasutenizol Achieves High Eradication Rate in Phase III H. pylori Trial
• TenNor Therapeutics' rifasutenizol triple therapy achieved a >90% eradication rate in treating _Helicobacter pylori_ (_H. pylori_) infection, surpassing the current standard bismuth-containing quadruple therapy (BQT).
• The Phase III trial (NCT05857163) demonstrated that the rifasutenizol regimen had a better safety and tolerability profile compared to BQT.
• High resistance rates were observed in patients treated with clarithromycin, metronidazole, levofloxacin, and amoxicillin, highlighting the growing issue of antimicrobial resistance in _H. pylori_ strains.
• Rifasutenizol, targeting anaerobic and microaerophile bacteria, could potentially become the first new drug specifically developed for _H. pylori_ infection in over 30 years.
TenNor's Rifasutenizol Demonstrates Superior Efficacy Against H. pylori in Phase III Trial
• TenNor Therapeutics' rifasutenizol-based triple therapy achieved a >90% eradication rate in treating Helicobacter pylori (H. pylori) infections, outperforming bismuth-containing quadruple therapy.
• The Phase III trial showed rifasutenizol's superiority (p=0.0338) in the mITT population and non-inferiority (p<0.0001) in both mITT and PP populations compared to the standard BQT regimen.
• Rifasutenizol maintained high efficacy against antibiotic-resistant H. pylori strains, showing a 90.9% eradication rate versus 87.2% with BQT (p<0.0001 for non-inferiority).
• The rifasutenizol regimen exhibited a better safety profile with fewer treatment-emergent adverse events compared to BQT, positioning it as a potential first-line treatment.
TenNor's Rifasutenizol Achieves High Eradication Rate in Phase III H. pylori Trial
• TenNor Therapeutics' rifasutenizol triple therapy achieved a >90% eradication rate in treating Helicobacter pylori (H. pylori) infection in a Phase III trial.
• The rifasutenizol regimen outperformed the current standard of care, bismuth-containing quadruple therapy (BQT), in H. pylori eradication.
• Rifasutenizol demonstrated a better safety and tolerability profile compared to BQT, with only 3% of patients dropping out of the trial.
• Rifasutenizol targets anaerobic and microaerophile bacteria and could be the first new drug specifically for H. pylori infection in over 30 years.
TenNor's Rifasutenizol Demonstrates Superior Efficacy Against H. pylori in Phase III Trial
• TenNor Therapeutics' rifasutenizol-based triple therapy achieved a >90% eradication rate in H. pylori-infected patients, surpassing the standard bismuth-containing quadruple therapy.
• The Phase III trial in China showed rifasutenizol was also more effective in patients with antibiotic-resistant H. pylori infections compared to the standard treatment.
• Rifasutenizol exhibited a better safety and tolerability profile than the bismuth-containing quadruple therapy, with fewer treatment-emergent adverse events.
• Rifasutenizol has the potential to be the first new drug developed specifically for H. pylori in over 30 years, offering a treatment option without requiring drug sensitivity tests.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath